frontotemporal dementia (FTD)

news

Scientists target ALS and dementia RNA using novel molecule

28 October 2021 | By Anna Begley (Drug Target Review)

The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

article

Getting “under the skin” of frontotemporal dementia

23 August 2021 | By Anna Begley (Drug Target Review)

Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.

article

How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy

13 July 2021 | By Dr Jim Burns (Locanabio)

In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.

news

Researchers identify a novel tau aggregation control mechanism

2 December 2020 | By Hannah Balfour (Drug Target Review)

According to researchers, the more small tau protein variants expressed by neurons, the slower neurofibrillary tangles form.

news

Dementia spreads via connected brain networks, finds study

15 October 2019 | By Victoria Rees (Drug Target Review)

New findings on dementia reveal that brain atrophy spreads via connected brain networks, rather than simply adjacent areas of the brain.

news

CRISPR helps find new genetic suspects behind ALS/FTD

13 March 2018 | By Dr Zara Kassam (Drug Target Review)

Study provides a roadmap for using CRISPR to investigate neurological disorders...